

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UM-06340

Serial No.: 09/878,603

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(Use Several Sheets If Necessary)Applicant: Peter A. Ward *et al.*

Filing Date: 06/11/01

Group Art Unit: 1644

(37 CFR § 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
AD	1	4,357,272	11/2/82	Polson	260	112	3/15/79
	2	5,051,448	9/24/91	Shashoua	514	547	5/7/90
	3	5,169,862	12/8/92	Burke, Jr., <i>et al.</i>	514	450	11/18/91
	4	5,192,746	3/9/93	Lobl, <i>et al.</i>	514	11	7/9/90
	5	5,260,203	11/9/93	Ladner <i>et al.</i>	435	172.3	4/25/90
	6	5,340,923	8/23/94	Carroll	530	389.1	11/17/92
	7	5,539,085	7/23/96	Bischoff, <i>et al.</i>	530	350	8/20/93
	8	5,559,103	9/24/96	Gaeta <i>et al.</i>	514	54	7/20/94
	9	5,565,332	10/15/96	Hoogenboom <i>et al.</i>	435	69.1	9/23/92
	10	5,576,423	11/19/96	Aversa <i>et al.</i>	530	388.75	12/2/94
	11	5,585,089	12/17/96	Queen <i>et al.</i>	424	133.1	6/7/95
	12	5,658,727	8/19/97	Barbas <i>et al.</i>	435	6	4/10/92
	13	5,904,922	5/18/99	Carroll	424	139.1	5/16/95

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	14	EP 025949	11/19/87	EPO				
AD	15	WO 96/39503	12/1996	PCT				
	16	EP 0 245 993	11/1987	EPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AD	17	Ames <i>et al.</i> , "Isolation of Neutralizing Anti-C5a Monoclonal Antibodies from a Filamentous Phage Monovalent Fab Display Library," <i>J. of Immunology</i> 152:4572-4581 (1994)
	18	Bone, "The Pathogenesis of Sepsis," <i>Ann. Intern. Med.</i> 115:457-469 (1991)
	19	Caplan <i>et al.</i> , "Infection Surveillance and Control in the Severely Traumatized Patient," <i>Am. J. Med.</i> 70:638-640 (1981)
	20	Caruthers <i>et al.</i> , "New chemical methods for synthesizing polynucleotides," <i>Nuc. Acids Res. Symp. Ser.</i> 7:215-233 (1980)
	21	Chow and Kempe, "Synthesis of oligodeoxyribonucleotides on silica gel support," <i>Nuc. Acids Res.</i> 9:2807-2817 (1981)
	22	Crea and Horn, "Synthesis of oligonucleotides on cellulose by a phosphotriester methods," <i>Nuc. Acids Res.</i> 9:2331 (1980)
	23	Creighton (1983) <i>Proteins Structures And Molecular Principles</i> , W H Freeman and Co, New York N.Y.]
	24	Czermak <i>et al.</i> , "Protective effects of C5a blockade in sepsis," <i>Nature</i> 5:788-792 (1999)
	25	<del>Davis <i>et al.</i>, <i>Basic Methods in Molecular Biology</i>, (1986)</del>
	26	Elzaim, <i>et al.</i> , "Generation of Neutralizing Antipeptide Antibodies to the Enzymatic Domain of <i>Pseudomonas aeruginosa</i> Exotoxin A," <i>Infect. Immun.</i> May;66(5):2170-9 (1998)
	27	Evans <i>et al.</i> , "An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies," <i>Nature</i> 339:385 (1989)
	28	Gerard, C. <i>et al.</i> , "Amino Acid Sequence of the Anaphylatoxin from the Fifth Component of Procine Complement," <i>J. Biol. Chem.</i> 255(10), 4710-4715, (1980)

Examiner:

Ann DeClune

Date Considered:

2-9-03

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900  
NOV 1 9 12 002  
RECEIVED

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UM-06340

Serial No.: 09/878,603

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(Use Several Sheets If Necessary)Applicant: Peter A. Ward *et al.*

Filing Date: 06/11/01

Group Art Unit: 1644

(37 CFR § 1.98(b))

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AD	29	Gluzman, "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants," <i>Cell</i> 23:175 [1981]
	30	Hatherill <i>et al.</i> , "Effects of Anti-C5a Antibodies on Human Polymorphonuclear Leukocyte Function: Chemotaxis, Chemiluminescence, and Lysosomal Enzyme Release," <i>Journal of Biological Response Modifiers</i> 8:614-624 (1989)
	31	Hill, J.H. and Ward, P.A., "The Phlogistic Role of C3 Leukotactic Fragments in Myocardial Infarcts of Rats," <i>J. Exp. Med.</i> 133:885-900, (1971)
	32	Hochuli <i>et al.</i> , "New Metal Chelate Adsorbent Selective For Proteins And Peptides Containing Neighbouring Histidine Residues," <i>J. Chromatography</i> 411:177 (1987)
	33	Hoffman <i>et al.</i> , "Prognostic Variables for Survival of Neonatal Foals Under Intensive Care," <i>J. Vet. Int. Med.</i> 6:89-95 (1992)
	34	Huang <i>et al.</i> , "Vaccinia Virus Recombinants Expressing an 11-Kilodalton $\beta$ -Galactosidase Fusion Protein Incorporate Active $\beta$ -Galactosidase in Virus Particles," <i>J. Virol.</i> 62:3855 (1988)
✓	35	Joklik <i>et al.</i> (eds.), "Streptococcus pneumoniae," <i>Zinsser Microbiology</i> , 18th ed., p. 485, Appleton-Century-Crofts, Norwalk, CT (1984)
	36	<del>Kenner, R.H., "Monoclonal Antibodies, Hybridoma--A New Dimension in Biological Analysis," Plenum Press, NY (1980)</del>
AD	37	Kettleborough, <i>et al.</i> , "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> , vol. 4, no.7, pp 773-783 (1991)
	38	Kohl, J., Bitter-Suermann, D., <i>Anaphylatoxins. Complement in health and disease.</i> , Edited by Whaley, K., Loos, M., Weiler, J.M., Kluwer Academic publishers, pp 299-324, (1993)
	39	Kohler, G. and Milstein, C., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> 256:495 (1975)
	40	Kola <i>et al.</i> , "Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis," <i>Immunotechnology</i> 1:115-126 (1996)
	41	Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes," <i>Immunol. Today</i> 4:72-79 (1983)
	42	Larrick <i>et al.</i> , "Characterization of Murine Monoclonal Antibodies That Recognize Neutralizing epitopes on Human C5a," <i>Infection and Immunity</i> 55:1867-1872 (Aug. 1987)
✓	43	Machiedo <i>et al.</i> , "Patterns Of Mortality In a Surgical Invasive Care Unit," <i>Surg. Gyn. &amp; Obstet.</i> 152:757-759 (1981)
	44	Mandecki W, <i>et al.</i> , "Chemical Synthesis of a gene encoding the human complement fragment C5a and its expression of <i>Escherichia coli</i> ," <i>Proc Natl Acad Sci U S A.</i> Jun;82(11):3543- 7(1985)
	45	Matteucci and Caruthers, "The Synthesis of Oligodeoxypyrimidines on a Polymer Support," <i>Tetrahedron Lett</i> 21:719 (1980)
	46	Meek <i>et al.</i> , "The Baltimore Sepsis Scale: Measurement of Sepsis in Patients with Burns Using a New Scoring System," <i>J. Burn Care Rehab.</i> 12:564-568 (1991)
	47	Mohr <i>et al.</i> , "Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis," <i>European Journal of Clinical Investigation</i> 28:227-234 (1998)
	48	Morris <i>et al.</i> , "Endotoxemia in neonatal calves given antiserum to a mutant <i>Escherichia coli</i> (J-5)," <i>Am. J. Vet. Res.</i> 47:2554-2565 (1986)
	49	Mulligan, M.S. <i>et al.</i> , "Requirement and Role of C5a in Acute Lung Inflammatory Injury in Rats," <i>J. Clin. Invest.</i> 98:503-512, 1996)
✓	50	Nardelli <i>et al.</i> , "A Chemically Defined Synthetic Vaccine Model for HIV-1," <i>J. Immunol.</i> 148:914 (1992)
	51	<del>NCBI Accession Number A57689</del>
	52	<del>NCBI Accession Number P01032</del>
	53	<del>NCBI Accession Number P12082</del>
AD	54	Nichols, "Classification of Surgical Wounds and Nonoperative Factors Influencing Surgical Wound Infection," <i>Decision Making in Surgical Sepsis</i> , B.C. Decker, Inc., Philadelphia, pp. 20-21 (1991)
	55	Nilsson <i>et al.</i> , "Affinity Fusion Strategies for Detection, Purification, and Immobilization of Recombinant Proteins," <i>Prot. Expr. Purif.</i> , 11(1):1-16 [1997]
✓	56	Olson <i>et al.</i> , "The Role of C5 in Septic Lung Injury," <i>Ann. Surg.</i> 202:771-776 (1985)

Examiner:

Am De Elune

Date Considered:

2-3-03

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UM-06340

Serial No.: 09/878,603

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(Use Several Sheets If Necessary)Applicant: Peter A. Ward *et al.*

Filing Date: 06/11/01

Group Art Unit: 1644

(37 CFR § 1.98(b))

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AD	57	Park <i>et al.</i> , "Attenuation of Endothelium-Dependent Dilation of Pig Pulmonary Arterioles After Cardiopulmonary Bypass is Prevented by Monoclonal Antibody to Complement C5a," <i>Anesth Analg</i> 89:42-9 (1999)
	58	Posnett <i>et al.</i> , "A Novel Method for Producing Anti-peptide Antibodies," <i>JBC</i> 263:1719 (1988)
	59	Roberge <i>et al.</i> , "A Strategy for a Convergent Synthesis of N-Linked Glycopeptides on a Solid Support," <i>Science</i> 269:202-204 (1995)
	60	Rothermel <i>et al.</i> "Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a <sup>1</sup> ," <i>Biochim. Biophys. Acta</i> 1351 (1-2), 9-12, (1997)
	61	Schlienger <i>et al.</i> , "Human Immunodeficiency Virus Type 1 Major Neutralizing Determinant Exposed on Hepatitis B Surface Antigen Particles Is Highly Immunogenic in Primates," <i>J. Virol.</i> 66:2 (1992)
	62	Schulman <i>et al.</i> , "Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis," <i>JAMA</i> 266:3466-3471 (1991)
	63	Slack and I.S. Snyder, <i>Bacteria and Human Disease</i> , pp. 128-133, Yearbook Medical Publishers (1978)
	64	Solomkin, J.S., <i>et al.</i> , "Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation," <i>Surgery</i> 90:319-327 (1981)
	65	Stahel, <i>et al.</i> , "TNF- $\alpha$ -Mediated Expression of the Receptor for Anaphylatoxin C5a on Neurons in Experimental <i>Listeria</i> Meningoencephalitis," <i>J. Immunol.</i> Jul. 15;159(2):861-9 (1997)
↓	66	Stevens <i>et al.</i> , "Effects of Anti-C5a Antibodies on the Adult Respiratory Distress Syndrome in Septic Primates," <i>J. Clin. Invest.</i> 77:1812-1816 (1986)
	<del>67</del>	<del>Stryer ed., <i>Biochemistry</i>, 2nd ed., W.H. Freeman, and Co. [1981]</del>
AD	68	Van Epps, <i>et al.</i> , "Relationship of C5a Receptor Modulation to the Functional Responsivness of Human Polymorphonuclear Leukocytes of C5a <sup>1</sup> ," <i>J. Immunol.</i> 150:246-252 (1993)
	69	Ward, P.A. & Becker, E.L., "The Deactivation of Rabbit Neutrophils by Chemotactic Factor and the Nature of the Activatable Esterase," <i>J. Exp. Med.</i> 127:693-709 (1968)
	70	Wilson <i>et al.</i> , "The Structure of an Antigenic Determinant in a Protein," <i>Cell</i> 37:767-778 (1984)
	71	Wolff, "Monoclonal Antibodies And The Treatment Of Gram-Negative Bacteremia And Shock," <i>New Eng. J. Med.</i> 324:486-488 (1991)
	72	Yousmans <i>et al.</i> , <i>Biologic and Clinical Basis of Infectious Diseases</i> , 3d ed., p. 553, W.B. Saunders Co., (1985)
	73	Zarbock, J., <i>et al.</i> , "A proton nuclear magnetic resonance study of the conformation of bovine anaphylatoxin C5a in solution," <i>FEBS Lett.</i> 238(2), 289-294, (1988)
↓	74	Zhong <i>et al.</i> , "Production, Specificity, nd Functionality of Monoclonal Antibodies to Specific Peptide-major Histocompatibility Complex Class II Complexes Formed by Processing of Exogenous Protein," <i>Proc. Natl. Acad. Sci. USA.</i> 94:13856-13861 (Dec., 1997)

Examiner:

Ann De Puma

Date Considered:

2-3-03

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.